Pipeline
Pioneering Next-Generation Therapeutics
Our highly diversified pipeline includes two wholly owned cancer immunotherapy drugs in clinical trials, several advanced preclinical programs and drug candidates, as well as a diversity of partnered programs in oncology, autoimmune and neurodegenerative diseases.
ORB-011 is an A-Kine® that is designed to bind to and selectively activate the tumor antigen presenting immune cell cDC1. Effector function is encoded by a specialized, on-target conditionally active interferon. Interferon is a potent promoter of cDC1 activities associated with tumor antigen presentation-mediated activation of CD8 T cells. Activated cDC1 cells may also communicate with and promote activity of NK cells, thus engaging both adaptive and innate immune mechanisms. cDC1 activation initiates antitumor response in both tumor microenvironment and tumor draining lymph nodes. ORB-011 is in a Phase 1 open-label dose escalation study for patients with recurrent or refractory solid tumors. The trial (NCT05947474) is designed to provide initial safety, pharmacokinetic and pharmacodynamic readouts.
ORB-021 is an A-Kine® that is designed to bind to and selectively modulate the function of tumor and immune cells that express the PD-L1 checkpoint marker. Antitumor activity of ORB-021 invokes activation of natural killer and dendritic cells, and inhibition of myeloid derived suppressor cells [MDSCs]. MDSCs in the tumor microenvironment are highly immune suppressive, and prevalent in “cold” tumors that are refractory to standard cancer (immuno)-therapies. ORB-021 is in a Phase 1 open-label dose escalation study for patients with recurrent or refractory solid tumors. The trial (NCT06607939) is designed to provide initial safety, pharmacokinetic and pharmacodynamic readouts.
Monovalent glues.
ORB-PR1 lymphoid programs comprise several A-Kine® and cell engager approaches to elicit CD8 T and/or NK cell-mediated antitumor responses. They include, for example, a unique set of CD8-targeted cytokines, including interleukins with distinct biological activities across subtypes of T cells. Two of these are in IND-enabling phase, others in advanced lead optimization. Specific target activation in vivo is associated potent antitumor activity at well tolerated doses in preclinical models of “cold” tumors. CD8 T cell activators have potential for activity across many cancer types. Additional molecules pertain to activation of NK cells in the tumor microenvironment.
ORB-PR2 myeloid programs comprise several A-Kine® and cell engager approaches that involve specific myeloid cells. They include different types of antigen presenting cells, including M2 macrophages and MDSCs. Molecules also include dendritic cell modulators and engagers designed to promote prevalence and strength of certain immune cell interactions to drive potency and durability of immune memory functions. Two of these are in IND-enabling phase, others at various stages of optimization for triage and selection of development candidates.
These include multiple molecular glues and biologics at various stages of optimization.